Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

McKinsey
Boehringer Ingelheim
Mallinckrodt
Johnson and Johnson
AstraZeneca
Merck

Last Updated: November 22, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,987,102

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 6,987,102 protect, and when does it expire?

Patent 6,987,102 protects MOZOBIL and is included in one NDA.

This patent has forty-three patent family members in twenty-seven countries.

Summary for Patent: 6,987,102
Title:Methods to mobilize progenitor/stem cells
Abstract:Certain nitrogen-containing compounds that bind the chemokine receptor CXCR4 are able to mobilize progenitor and/or stem cells into the peripheral blood to permit harvesting them for stem cell transplantation.
Inventor(s): Bridger; Gary J. (Bellingham, WA), Abrams; Michael J. (Custer, WA), Henson; Geoffrey W. (Ferndale, WA), MacFarland; Ronald Trevor (Vancouver, CA), Calandra; Gary B. (Cresco, PA), Broxmeyer; Hal E. (Indianapolis, IN), Dale; David C. (Seattle, WA)
Assignee: Anormed, Inc. (Langley, CA)
Application Number:10/209,001
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,987,102
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 6,987,102

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Genzyme MOZOBIL plerixafor SOLUTION;SUBCUTANEOUS 022311-001 Dec 15, 2008 RX Yes Yes   Start Trial   Start Trial USE IN COMBINATION WITH GRANULOCYTE-COLONY STIMULATING FACTOR (G-CSF) TO MOBILIZE HEMATOPOIETIC STEM CELLS TO PERIPHERAL BLOOD FOR COLLECTION & SUBSEQUENT AUTOLOGOUS TRANSPLANTATION IN PATIENTS WITH NON-HODGKIN'S LYMPHOMA & MULTIPLE MYELOMA   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Mallinckrodt
Harvard Business School
Colorcon
Moodys
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.